$1bn market for urban lung cancer in China in 2021
This article was originally published in Scrip
Executive Summary
The market for non-small cell lung cancer (NSCLC) drugs in China is set to rise from $707 million this year to $933 million in major cities by 2021 as uptake of targeted therapies increases.